Novo Nordisk, a leading biopharmaceutical company, is asserting confidence in its next-generation obesity drug candidate, CagriSema, despite recent concerns over trial results. The company’s CEO addressed these issues in a recent media call, focusing on dosage flexibility and the drug’s biological potential.
About the Author
